Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...

SEATTLE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

SEATTLE, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Even the best cancer treatments that remove the bulk of a tumour will rarely eradicate 100% of malignant cells. Any missed cells can remain active and pose a risk of relapse, but are often present in ...

CEO Anthony Zook highlighted record clinical volumes and revenues for the third quarter of 2025, emphasizing the company’s progress in next-generation sequencing (NGS) and minimal residual disease ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinical uses ...

ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Four clinical trials to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition illustrate how advancements in ...